In a bid to bolster the biopharmaceutical and health industries, the cities of Guangzhou and Zhuhai in Guangdong province have released Measures aimed at “Promoting High-Quality Development of the Biopharmaceutical Industry.” These policies are designed to refine the development environment and enhance the competitive edge of the sector.
Guangzhou’s policy, set to take effect on April 4, 2024, for a duration of three years, targets biopharmaceutical enterprises operating within the Guangzhou Development District and its affiliated parks. It offers comprehensive support to top-tier global projects, with a maximum backing of RMB 5 billion over a period of up to 5 years. The policy also provides a 30% support rate, capped at RMB 100 million, for national-level platform achievement transformation and industrialization projects. Support for innovative drugs, modified drugs, and biosimilars ranges from RMB 10 to 30 million, contingent upon the progress of clinical research and development. Additionally, the policy extends funding from RMB 300,000 to RMB 10 million for innovative drugs that secure clinical approvals or registration certificates from the NMPA and/or FDA. The document encompasses various levels of support for technology platform construction, CRO development, hospital access for innovative products, and clinical adoption of nationally negotiated drugs.
Zhuhai’s policy, applicable to biopharmaceutical enterprises within the city’s limits (excluding the Guangdong Macao In-Depth Cooperation Zone in Hengqin), is set to commence from April 1, 2024, through December 31, 2027. It offers rewards between RMB 3 million to RMB 10 million for innovative drugs based on their R&D stage, with a maximum reward of RMB 10 million for those approved for marketing and commercialization. Innovative high-end formulations receiving their first approvals, breakthrough therapy designations, or conditional approvals are eligible for an additional RMB 1 million. Approved and marketed innovative devices can receive rewards of RMB 1-2 million. The policy also provides a maximum reward of RMB 2 million for drugs ranking in the top three that pass generic quality consistency evaluation. A 3% subsidy of the total procurement amount is offered to winning varieties in volume-based procurement for the current year, not exceeding RMB 3 million. For introduced products with a cumulative sales volume of not less than RMB 20 million, a reward of 15% of the project’s fixed assets investment is proposed, up to a maximum of RMB 10 million. The document also outlines various support plans for biopharmaceutical park construction, CRO/CDMO development, R&D platform sharing, facilitation of import and export customs clearance, medical enterprise linkage, and achievement translation.- Flcube.com
